LUMEN
Lumen , the creators of the world's first metabolism measurement device through the breath, have teamed up with the UK's top personal trainer, Harry Jameson, to raise awareness on metabolic health for March Metabolism Awareness Month .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210309005629/en/
Harry is available for expert commentary on training to improve your metabolism.
"Having the ability to move between energy sources (fat and carbohydrates) is extremely important. It is a measure of your metabolic health and I’ve been working hard over the past two months to improve mine.
Using Lumen to track whether my diet, fasting or even training is pushing my metabolism in the right direction has been both fascinating from a coaches perspective and incredibly insightful from a user/customer perspective. I love how lumen keeps me both accountable and consistent with my behaviours and getting personalised nutrition plans really helps take a mental load off my shoulders in my busy schedule," says personal trainer Jameson.
Lumen and Jameson are also working together to emphasise the importance of metabolic health in combating metabolic syndrome. In the UK, 1 in 3 adults over the age of 50 will suffer from metabolic disease which is a combination of diabetes, high blood pressure (hypertension) and obesity.
The power to move away from metabolic disease by training your metabolism to switch efficiently between carbs and fats as a fuel source is a term called metabolic flexibility .
"If we feed and train our metabolism, we can process our food more efficiently - you may be able to eat a slice of pie and use it for energy faster if you have a good metabolism. We are merely training our body to use fuel sources properly- an innate mechanism. There's really no need to crash diet , if we take care of our metabolism everything else follows", says PHD in nutrition and founder of Lumen, Michal Mor.
According to research data obtained by 1 million metabolism measurements through the Lumen device, users are able to:
- Lose an average of 0.5 kg or 1.5 pounds of weight per week on a consistent basis
- Improve their metabolic flexibility by 66%
- Improve fasting windows to 12 hours daily
- Increase their daily movement by 1000 steps
Research also (Calcada et al , Gormsen et al ) finds that metabolic flexibility has a profound role in assessing a person's long-term health. People with good metabolic flexibility:
- Are at lower risk of developing obesity, diabetes and metabolic disorders.
- Are in a better position to gain muscle and perform better during workouts;
- Find it easier to lose weight and maintain it
Lumen is the only device in the world to measure your metabolism through the breath and track your metabolic health to prevent diseases born out of poor nutrition.
Based on the traditional RER test which was once available only in hospitals or clinics, is accessible to anyone and anywhere for the first time-revolutionizing the way we approach weight loss, fitness and healthy nutrition decision making.
Through the co2 in your breath, Lumen measures your metabolism and provides an insight into whether you're burning fats or carbs in less than a minute.
Scientific Validation
Lumen can provide numerous insights about the metabolism of an individual, as well as valuable scientific data to increase knowledge of metabolic flexibility and nutrition. In a study conducted by San Francisco State University, Lumen has been validated to meet the gold standard for metabolic measurement.
Availability
The Lumen device is available at Lumen.me , currently priced at £299.
The device comes equipped with a travel case, charging dock, USB-C Cable, and Premium Customer Support. Users can download the app for free on the Apple App Store and on Google Play.
For media: images, video and fact sheet can be found in the press kit here.
About Lumen
Lumen helps people improve their health and fitness through technology on the forefront of personalized nutrition and metabolism. Conceived and designed by twin sisters, physiology PhDs and Ironman winners, Lumen harnesses the power of our breath to measure metabolism, which is closely linked to weight, fitness and personal health. The Lumen device measures metabolism in a single breath, in less than a minute, which previously was only possible through an hour-long lab test. Available at Lumen.me , Lumen devices ship globally, with the app available on the Apple App Store and Google Play. Lumen is headquartered in Israel, with offices in the United States.
[1] Sources: The role of low-grade inflammation and metabolic flexibility in aging and nutritional modulation thereof: A systems biology approach. Available via: https://www.sciencedirect.com/science/article/pii/S0047637414000050 . Last accessed 5 May 2020.
[2] Source: Estradiol acutely inhibits whole body lipid oxidation and attenuates lipolysis in subcutaneous adipose tissue: a randomized, placebo-controlled study in postmenopausal women. Available via:https://eje.bioscientifica.com/view/journals/eje/167/4/543.xml
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005629/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Transition Industries Signs Strategic Agreements for the Pacifico Mexinol Project, the Largest Standalone Ultra-Low Carbon Chemical Production Facility in the World30.6.2025 20:30:00 CEST | Press release
Pacifico Mexinol project, a 6,130 MT per day ultra-low carbon methanol production facility worth more than US$3.3b will be located near Topolobampo, Ahome, Sinaloa. Once operational in 2029, Pacifico Mexinol is poised to be the largest standalone ultra-low carbon chemical production facility in the world. Transition Industries LLC, a developer of world-scale, net-zero carbon emissions methanol and green hydrogen projects in North America, held a signing event for an Engineering, Procurement, and Construction (EPC) contract with the consortium of Samsung E&A Co., Ltd. (Samsung E&A), Grupo Samsung E&A Mexico, S.A. de C.V., and Techint Engineering and Construction for the Pacifico Mexinol project located in Ahome, Sinaloa, Mexico, which is contingent upon the fulfillment of customary conditions precedent and obtainment of all required approvals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630940954/en/ MAIRE group’s techn
Westinghouse and ITER Sign a $180M Contract to Advance Nuclear Fusion30.6.2025 15:45:00 CEST | Press release
The contract includes the assembly of the fusion reactor’s vacuum vessel, a key milestone which gets the project closer to replicating fusion energy on Earth Westinghouse Electric Company and ITER signed a contract for $180 million for the assembly of the vacuum vessel for the fusion reactor. This is a key milestone in the construction of the ITER reactor, leading the way toward the use of fusion as a practical future source of reliable carbon-free energy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630497810/en/ The ITER Tokamak pit with the two vacuum vessel sector modules installed. Westinghouse has participated in the fabrication of the sectors of the vacuum vessel, as part of the Fusion for Energy (F4E) Consortium with its partners Ansaldo Nucleare and Walter Tosto. Westinghouse will be responsible for completing the vacuum vessel which is ITER’s most critical component: a hermetically sealed, double-walled steel
Monetate Acquires SiteSpect to Deliver AI-Native Personalization and Testing at Enterprise Scale30.6.2025 15:00:00 CEST | Press release
Monetate’s Real-Time Personalization Unites with SiteSpect’s Zero-Flicker Testing to Optimize Digital Experiences with Unmatched Speed, Precision, and SecurityNow Global Ecommerce and Digital Experience Leaders Can Access a Best-in-Class, Enterprise-Grade Personalization, Testing, and Optimization Platform Monetate, the leading AI-driven personalization platform, today announced it has acquired SiteSpect, a leader in A/B testing, to drive next-generation digital experience optimization. This acquisition accelerates Monetate’s vision to deliver intelligent, intentional, and individualized experiences at scale, powered by agentic AI and backed by the industry’s most advanced, enterprise-grade infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630514541/en/ The combination of Monetate’s real-time personalization and SiteSpect’s zero-flicker testing will yield an industry-first solution for enterprise-grade person
SS&C Blue Prism Recognized as a Gartner® Magic Quadrant™ RPA Leader for the Seventh Consecutive Year30.6.2025 15:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that SS&C Blue Prism has been recognized as a Leader in the 2025 Gartner Magic Quadrant for Robotic Process Automation (RPA). “We’re delighted SS&C Blue Prism has been named a Leader in the Gartner Magic Quadrant for Robotic Process Automation for the seventh year running,” said Bill Stone, CEO and Chairman of SS&C Technologies. “SS&C Blue Prism combines market-leading RPA and orchestration technologies with the latest artificial intelligence so organizations can tackle more complex tasks and dynamic business processes. We’ve scaled to more than 2,700 digital workers and AI agents across our own operations, resulting in over $200 million in annual savings. With SS&C leading the charge on deployment, customers can be confident in rolling out SS&C’s automation solutions securely, effectively, and responsibly.” More than 2,800 companies worldwide leverage SS&C Blue Prism for AI-powered automation, helping organizations delive
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content130.6.2025 14:00:00 CEST | Press release
GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Approved for Intravenous or Subcutaneous Use in People Aged Two and Older with Primary Immunodeficiency1U.S. Commercialization of GAMMAGARD LIQUID ERC Projected to Begin in 2026Company Announces Future Manufacturing Discontinuation End Date for Takeda's First-Generation Low-IgA Product, A Freeze-Dried Formulation in Company’s Differentiated Immunoglobulin Portfolio of Ready-to-Use Liquids2 Takeda(TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency (PI). As a ready-to-use liquid, GAMMAGARD LIQUID ERC may help ease the administratio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom